Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
McKesson
Moodys
Johnson and Johnson
Boehringer Ingelheim

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 7,655,227

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 7,655,227
Title:Agents for ameliorating low vasopressin level
Abstract: The present invention provides an agent for ameliorating low vasopressin level, which comprises, as an active ingredient, a substance capable of inhibiting the binding between parathyroid hormone-related peptide (PTHrP) and a receptor thereof; and an agent for ameliorating a symptom caused by a decrease in vasopressin level, which comprises, as an active ingredient, a substance capable of inhibiting the binding between parathyroid hormone-related peptide (PTHrP) and a receptor thereof.
Inventor(s): Ogata; Etsuro (Tokyo, JP), Onuma; Etsuro (Shizuoka, JP), Tsunenari; Toshiaki (Shizuoka, JP), Saito; Hidemi (Shizuoka, JP), Azuma; Yumiko (Shizuoka, JP)
Assignee: Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP)
Application Number:10/019,501
Patent Claims:1. A method of treating hyperosmolarity caused by a decrease in vasopressin level in blood comprising administering to a patient at least one humanized anti-parathyroid hormone related protein 1-34 (anti-PTHrP (1-34)) antibody, or a binding fragment thereof that binds to SEQ ID NO: 75 in an amount sufficient to inhibit the decrease in vasopressin level in the blood of the patient, wherein said at least one humanized anti-parathyroid hormone related protein 1-34 (anti-PTHrP (1-34)) antibody, or binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 56 and a light chain variable region comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 47, 48, 49, 50, 51, 52, 53, 54 and 55.

2. The method according to claim 1, wherein the decrease in vasopressin level results from cancer.

3. The method according to claim 1, wherein the binding fragment is Fab, scFv, F(ab').sub.2 or Fv.

4. The method according to claim 1, wherein the antibody is a monoclonal antibody.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Mallinckrodt
Express Scripts
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.